Immunic (NASDAQ:IMUX) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a report released on Tuesday morning, Zacks.com reports.

According to Zacks, “Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis and psoriasis. The company’s product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. “

A number of other equities research analysts have also weighed in on the stock. ValuEngine upgraded shares of Immunic from a hold rating to a buy rating in a report on Thursday, August 1st. Chardan Capital set a $40.00 price objective on shares of Immunic and gave the stock a buy rating in a report on Friday, September 6th.

Shares of IMUX traded down $0.50 during mid-day trading on Tuesday, reaching $13.91. The company’s stock had a trading volume of 55,536 shares, compared to its average volume of 35,909. The firm has a market capitalization of $15.25 million, a PE ratio of -0.39 and a beta of 3.59. Immunic has a 52 week low of $6.00 and a 52 week high of $46.80. The stock’s fifty day moving average price is $13.91.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.80). As a group, research analysts expect that Immunic will post -3.78 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC bought a new stake in shares of Immunic in the 2nd quarter worth approximately $33,000. Vanguard Group Inc. purchased a new position in shares of Immunic in the second quarter worth $132,000. BlackRock Inc. purchased a new position in shares of Immunic in the second quarter worth $145,000. Independent Advisor Alliance purchased a new position in shares of Immunic in the second quarter worth $804,000. Finally, Omega Fund Management LLC purchased a new position in shares of Immunic in the second quarter worth $15,731,000.

About Immunic

Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.

Featured Article: What is a dividend reinvestment plan?

Get a free copy of the Zacks research report on Immunic (IMUX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.